Neil W Gibson
Overview
Explore the profile of Neil W Gibson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van der Ree M, de Vree J, Stelma F, Willemse S, Van Der Valk M, Rietdijk S, et al.
Lancet
. 2017 Jan;
389(10070):709-717.
PMID: 28087069
Background: miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of...
2.
Ma W, Gutierrez A, Goff D, Geron I, Sadarangani A, Jamieson C, et al.
PLoS One
. 2012 Jul;
7(6):e39725.
PMID: 22768113
Background: Leukemia initiating cells (LIC) contribute to therapeutic resistance through acquisition of mutations in signaling pathways, such as NOTCH1, that promote self-renewal and survival within supportive niches. Activating mutations in...
3.
Wang K, Kan J, Yuen S, Shi S, Chu K, Law S, et al.
Nat Genet
. 2011 Nov;
43(12):1219-23.
PMID: 22037554
Gastric cancer is a heterogeneous disease with multiple environmental etiologies and alternative pathways of carcinogenesis. Beyond mutations in TP53, alterations in other genes or pathways account for only small subsets...
4.
Bhagwat S, Gokhale P, Crew A, Cooke A, Yao Y, Mantis C, et al.
Mol Cancer Ther
. 2011 Jun;
10(8):1394-406.
PMID: 21673091
The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target. mTOR forms two distinct multiprotein complexes, mTORC1 and mTORC2, which regulate cell...
5.
Mulvihill M, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, et al.
Future Med Chem
. 2011 Mar;
1(6):1153-71.
PMID: 21425998
Background: The IGF-1 receptor (IGF-1R) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has become a major focus for the development...
6.
Crew A, Bhagwat S, Dong H, Bittner M, Chan A, Chen X, et al.
Bioorg Med Chem Lett
. 2011 Mar;
21(7):2092-7.
PMID: 21353551
The discovery and optimization of a series of imidazo[1,5-a]pyrazine inhibitors of mTOR is described. HTS hits were optimized for potency, selectivity and metabolic stability to provide the orally bioavailable proof...
7.
Lamb J, Gibson N
Sci Transl Med
. 2010 Apr;
2(25):25cm11.
PMID: 20424010
The Commentary of Mills and Sykes in Science Translational Medicine presented their thesis on the advent of high-throughput technologies and the dangers they may represent for the future of biomedical...
8.
Wang J, Rajput A, Kan J, Rose R, Liu X, Kuropatwinski K, et al.
J Biol Chem
. 2009 Feb;
284(16):10912-22.
PMID: 19224914
Abnormal accumulation and activation of receptor tyrosine kinase Ron (recepteur d'origine nantais) has been demonstrated in a variety of primary human cancers. We show that RNA interference-mediated knockdown of Ron...
9.
Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al.
Cancer Res
. 2008 Oct;
68(20):8322-32.
PMID: 18922904
Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR) can cooperate to regulate tumor growth and survival, and synergistic growth inhibition has been reported for combined blockade of...
10.
Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al.
Clin Exp Metastasis
. 2008 Feb;
25(6):685-93.
PMID: 18236164
Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mesenchymal characteristics which contribute to...